Iridex Corporation Regains Compliance with Nasdaq Listing Rules

Iridex Corporation, a global leader in developing laser-based medical systems for treating glaucoma and retinal diseases, has received formal notice from the Nasdaq Stock Market LLC that it has regained compliance with the continued listing standards. This follows a previous notification of non-compliance in May 2025, which was resolved after the company met the minimum stockholders' equity requirement of $2,500,000 in June 2025. Iridex's proprietary MicroPulse technology has been successful in treating sight-threatening eye conditions, and the company's products are sold in over 100 countries.

Key Takeaways:

• Iridex Corporation has received formal notice from Nasdaq indicating compliance with continued listing requirements, resolving the non-compliance issue from May 2025.
• The company satisfied the minimum stockholders' equity requirement of $2,500,000 for continued listing on the Nasdaq Capital Market in June 2025.
• Iridex's proprietary MicroPulse technology has been successful in treating glaucoma, diabetic macular edema (DME), and other retinal diseases.
• The company's products are sold in the United States through a direct sales force and internationally through a network of independent distributors.
• Iridex has a global presence with sales in over 100 countries.

Statistics:

• Iridex received formal notice of non-compliance from Nasdaq on May 14, 2025.
• The company regained compliance with Nasdaq Listing Rule 5550(b) on August 27, 2025.
• The minimum stockholders' equity requirement for continued listing on the Nasdaq Capital Market is $2,500,000, as stated in Nasdaq Listing Rule 5550(b)(1).
• Iridex has a direct sales force in the United States and a network of independent distributors for international markets.

Sources:

• GLOBE NEWSWIRE, MOUNTAIN VIEW, Calif., Sept. 09, 2025, Iridex Corporation Regains Compliance with Nasdaq Listing Rules
• Iridex Corporation, www.iridex.com
• Nasdaq Listing Rule 5550(b)(1)